A 28-Day Study Evaluating the Safety of Ragweed (Ambrosia Artemisiifolia) Allergy Immunotherapy Tablet (SCH 39641/MK-3641) Treatment in Ragweed Allergic Adults (Phase 3, Protocol No.P05751).

Trial Profile

A 28-Day Study Evaluating the Safety of Ragweed (Ambrosia Artemisiifolia) Allergy Immunotherapy Tablet (SCH 39641/MK-3641) Treatment in Ragweed Allergic Adults (Phase 3, Protocol No.P05751).

Completed
Phase of Trial: Phase III

Latest Information Update: 07 Mar 2017

At a glance

  • Drugs Short ragweed pollen allergen extract (Ragwitek) (Primary)
  • Indications Rhinoconjunctivitis
  • Focus Adverse reactions
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 24 Apr 2012 Actual patient number (914) added as reported by ClinicalTrials.gov.
    • 24 Apr 2012 Actual end date (Apr 2012) added as reported by ClinicalTrials.gov.
    • 24 Apr 2012 Actual initiation date changed from Oct 2011 to Nov 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top